Psilocybin
IRB#7950
Phase 2 small_molecule completed
Quick answer
Psilocybin for Body Dysmorphic Disorders is a Phase 2 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Compass Therapeutics
- Indication
- Body Dysmorphic Disorders
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed